{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:55:47Z","timestamp":1793130947878,"version":"4.5.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA233490"],"award-info":[{"award-number":["R01CA233490"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer institute","doi-asserted-by":"crossref","award":["R01CA138688"],"award-info":[{"award-number":["R01CA138688"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["1RC1CA146299"],"award-info":[{"award-number":["1RC1CA146299"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["R01CA187415"],"award-info":[{"award-number":["R01CA187415"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0730-x","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T10:26:01Z","timestamp":1571826361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies"],"prefix":"10.1136","volume":"7","author":[{"given":"Zijun Y.","family":"Xu-Monette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beryl","family":"Crossley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Bremel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganiraju C.","family":"Manyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandar","family":"Tzankov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dybkaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Han","family":"van Krieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jooryung","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurilio","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J. M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Piris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"issue":"6","key":"730_CR1","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/eji.1830270616","volume":"27","author":"R Kuppers","year":"1997","unstructured":"Kuppers R, Rajewsky K, Hansmann ML. Diffuse large cell lymphomas are derived from mature B cells carrying V region genes with a high load of somatic mutation and evidence of selection for antibody expression. Eur J Immunol. 1997;27(6):1398\u2013405.","journal-title":"Eur J Immunol"},{"issue":"6844","key":"730_CR2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","volume":"412","author":"L Pasqualucci","year":"2001","unstructured":"Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412(6844):341\u20136.","journal-title":"Nature."},{"issue":"3","key":"730_CR3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nri3804","volume":"15","author":"NS Silva De","year":"2015","unstructured":"De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 2015;15(3):137\u201348.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"730_CR4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.18632\/oncoscience.155","volume":"2","author":"S Rebhandl","year":"2015","unstructured":"Rebhandl S, Huemer M, Greil R, Geisberger R. AID\/APOBEC deaminases and cancer. Oncoscience. 2015;2(4):320\u201333.","journal-title":"Oncoscience."},{"issue":"6","key":"730_CR5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrc.2016.40","volume":"16","author":"MR Lieber","year":"2016","unstructured":"Lieber MR. Mechanisms of human lymphoid chromosomal translocations. Nat Rev Cancer. 2016;16(6):387\u201398.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"730_CR6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/blood.V96.3.808","volume":"96","author":"TG Willis","year":"2000","unstructured":"Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000;96(3):808\u201322.","journal-title":"Blood."},{"issue":"3","key":"730_CR7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20062041","volume":"204","author":"G Lenz","year":"2007","unstructured":"Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007;204(3):633\u201343.","journal-title":"J Exp Med"},{"issue":"15","key":"730_CR8","doi-asserted-by":"crossref","first-page":"13229","DOI":"10.18632\/oncotarget.3644","volume":"6","author":"G Cowan","year":"2015","unstructured":"Cowan G, Weston-Bell NJ, Bryant D, Seckinger A, Hose D, Zojer N, et al. Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma. Oncotarget. 2015;6(15):13229\u201340.","journal-title":"Oncotarget."},{"issue":"12","key":"730_CR9","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1002\/eji.201344421","volume":"44","author":"M Huemer","year":"2014","unstructured":"Huemer M, Rebhandl S, Zaborsky N, Gassner FJ, Hainzl S, Weiss L, et al. AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells. Eur J Immunol. 2014;44(12):3747\u201357.","journal-title":"Eur J Immunol"},{"issue":"18","key":"730_CR10","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1073\/pnas.180316097","volume":"97","author":"IS Lossos","year":"2000","unstructured":"Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A. 2000;97(18):10209\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"730_CR11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","volume":"139","author":"L Srinivasan","year":"2009","unstructured":"Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139(3):573\u201386.","journal-title":"Cell."},{"issue":"8","key":"730_CR12","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2016-10-747303","volume":"130","author":"O Havranek","year":"2017","unstructured":"Havranek O, Xu J, Kohrer S, Wang Z, Becker L, Comer JM, et al. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood. 2017;130(8):995\u20131006.","journal-title":"Blood."},{"issue":"3","key":"730_CR13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","volume":"130","author":"T Erdmann","year":"2017","unstructured":"Erdmann T, Klener P, Lynch JT, Grau M, Vockova P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130(3):310\u201322.","journal-title":"Blood."},{"issue":"44","key":"730_CR14","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1073\/pnas.1514944112","volume":"112","author":"RM Young","year":"2015","unstructured":"Young RM, Wu T, Schmitz R, Dawood M, Xiao W, Phelan JD, et al. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proc Natl Acad Sci U S A. 2015;112(44):13447\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"730_CR15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0092-8674(91)90506-T","volume":"64","author":"S Weiss","year":"1991","unstructured":"Weiss S, Bogen B. MHC class II-restricted presentation of intracellular antigen. Cell. 1991;64(4):767\u201376.","journal-title":"Cell."},{"issue":"6","key":"730_CR16","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.4049\/jimmunol.1400075","volume":"193","author":"H Macmillan","year":"2014","unstructured":"Macmillan H, Strohman MJ, Ayyangar S, Jiang W, Rajasekaran N, Spura A, et al. The MHC class II cofactor HLA-DM interacts with Ig in B cells. J Immunol. 2014;193(6):2641\u201350.","journal-title":"J Immunol"},{"issue":"5","key":"730_CR17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0008-8749(92)90259-R","volume":"69","author":"D Chakrabarti","year":"1992","unstructured":"Chakrabarti D, Hosh SK. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. III. MHC class I-restricted CTL recognizes the processed form(s) of idiotype. Cell Immunol. 1992;69(5):455\u201364.","journal-title":"Cell Immunol"},{"issue":"7647","key":"730_CR18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","volume":"543","author":"MS Khodadoust","year":"2017","unstructured":"Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature. 2017;543(7647):723\u20137.","journal-title":"Nature."},{"issue":"8","key":"730_CR19","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","volume":"133","author":"MS Khodadoust","year":"2019","unstructured":"Khodadoust MS, Olsson N, Chen B, Sworder B, Shree T, Liu CL, et al. B-cell lymphomas present immunoglobulin neoantigens. Blood. 2019;133(8):878\u201381.","journal-title":"Blood."},{"issue":"46","key":"730_CR20","doi-asserted-by":"crossref","first-page":"12190","DOI":"10.1073\/pnas.1613140114","volume":"114","author":"RM Pielak","year":"2017","unstructured":"Pielak RM, O'Donoghue GP, Lin JJ, Alfieri KN, Fay NC, Low-Nam ST, et al. Early T cell receptor signals globally modulate ligand:receptor affinities during antigen discrimination. Proc Natl Acad Sci U S A. 2017;114(46):12190\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"730_CR21","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3389\/fimmu.2017.01597","volume":"8","author":"ZY Xu-Monette","year":"2017","unstructured":"Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response? Front Immunol. 2017;8:1597.","journal-title":"Front Immunol"},{"key":"730_CR22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3389\/fimmu.2014.00541","volume":"5","author":"RD Bremel","year":"2014","unstructured":"Bremel RD, Homan EJ. Frequency patterns of T-cell exposed amino acid motifs in immunoglobulin heavy chain peptides presented by MHCs. Front Immunol. 2014;5:541.","journal-title":"Front Immunol"},{"key":"730_CR23","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3389\/fimmu.2015.00538","volume":"6","author":"RD Bremel","year":"2015","unstructured":"Bremel RD, Homan EJ. Extensive T-cell epitope repertoire sharing among human proteome, gastrointestinal microbiome, and pathogenic bacteria: implications for the definition of self. Front Immunol. 2015;6:538.","journal-title":"Front Immunol"},{"issue":"9","key":"730_CR24","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","volume":"26","author":"C Visco","year":"2012","unstructured":"Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the international DLBCL rituximab-CHOP consortium program study. Leukemia. 2012;26(9):2103\u201313.","journal-title":"Leukemia."},{"issue":"19","key":"730_CR25","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an international DLBCL rituximab-CHOP consortium program study. Blood. 2012;120(19):3986\u201396.","journal-title":"Blood."},{"issue":"12","key":"730_CR26","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1200\/JCO.2014.57.7080","volume":"33","author":"K Dybkaer","year":"2015","unstructured":"Dybkaer K, Bogsted M, Falgreen S, Bodker JS, Kjeldsen MK, Schmitz A, et al. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol. 2015;33(12):1379\u201388.","journal-title":"J Clin Oncol"},{"issue":"7","key":"730_CR27","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/modpathol.2013.214","volume":"27","author":"A Tzankov","year":"2014","unstructured":"Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014;27(7):958\u201371.","journal-title":"Mod Pathol"},{"issue":"2","key":"730_CR28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2012.066209","volume":"98","author":"C Visco","year":"2013","unstructured":"Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an international DLBCL rituximab-CHOP consortium program study. Haematologica. 2013;98(2):255\u201363.","journal-title":"Haematologica."},{"issue":"14","key":"730_CR29","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1158\/1078-0432.CCR-15-2296","volume":"22","author":"ZY Xu-Monette","year":"2016","unstructured":"Xu-Monette ZY, Deng Q, Manyam GC, Tzankov A, Li L, Xia Y, et al. Clinical and biologic significance of MYC genetic mutations in De novo diffuse large B-cell lymphoma. Clin Cancer Res. 2016;22(14):3593\u2013605.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"730_CR30","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.4049\/jimmunol.1201303","volume":"189","author":"K Larimore","year":"2012","unstructured":"Larimore K, McCormick MW, Robins HS, Greenberg PD. Shaping of human germline IgH repertoires revealed by deep sequencing. J Immunol. 2012;189(6):3221\u201330.","journal-title":"J Immunol"},{"issue":"17","key":"730_CR31","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-13-3231","volume":"20","author":"D Wu","year":"2014","unstructured":"Wu D, Emerson RO, Sherwood A, Loh ML, Angiolillo A, Howie B, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014;20(17):4540\u20138.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"730_CR32","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","volume":"131","author":"B Wood","year":"2018","unstructured":"Wood B, Wu D, Crossley B, Dai Y, Williamson D, Gawad C, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018;131(12):1350\u20139.","journal-title":"Blood."},{"issue":"6","key":"730_CR33","first-page":"595","volume":"2011","author":"MP Lefranc","year":"2011","unstructured":"Lefranc MP. IMGT, the international ImMunoGeneTics information system. Cold Spring Harb Protoc. 2011;2011(6):595\u2013603.","journal-title":"Cold Spring Harb Protoc"},{"issue":"5","key":"730_CR34","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.ajpath.2012.07.028","volume":"181","author":"E Sebastian","year":"2012","unstructured":"Sebastian E, Alcoceba M, Balanzategui A, Marin L, Montes-Moreno S, Flores T, et al. Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. Am J Pathol. 2012;181(5):1879\u201388.","journal-title":"Am J Pathol"},{"issue":"11","key":"730_CR35","first-page":"1259","volume":"88","author":"VM Duke","year":"2003","unstructured":"Duke VM, Gandini D, Sherrington PD, Lin K, Heelan B, Amlot P, et al. V(H) gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia. Haematologica. 2003;88(11):1259\u201371.","journal-title":"Haematologica."},{"issue":"1","key":"730_CR36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1745-7580-6-8","volume":"6","author":"RD Bremel","year":"2010","unstructured":"Bremel RD, Homan EJ. An integrated approach to epitope analysis II: a system for proteomic-scale prediction of immunological characteristics. ImmunomeRes. 2010;6(1):8.","journal-title":"ImmunomeRes."},{"issue":"Pt. 1\u20132","key":"730_CR37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/biomet\/36.1-2.149","volume":"36","author":"NL Johnson","year":"1949","unstructured":"Johnson NL. Systems of frequency curves generated by methods of translation. Biometrika. 1949;36(Pt. 1\u20132):149\u201376.","journal-title":"Biometrika."},{"key":"730_CR38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.immunol.23.021704.115658","volume":"24","author":"MG Rudolph","year":"2006","unstructured":"Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol. 2006;24:419\u201366.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"730_CR39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.86.1.282","volume":"86","author":"S Weiss","year":"1989","unstructured":"Weiss S, Bogen B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci U S A. 1989;86(1):282\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"730_CR40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160853","volume":"11","author":"WS DeWitt","year":"2016","unstructured":"DeWitt WS, Lindau P, Snyder TM, Sherwood AM, Vignali M, Carlson CS, et al. A public database of memory and naive B-cell receptor sequences. PLoS One. 2016;11(8):e0160853.","journal-title":"PLoS One"},{"issue":"4","key":"730_CR41","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2326-6066.CIR-18-0439","volume":"7","author":"ZY Xu-Monette","year":"2019","unstructured":"Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, et al. Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL. Cancer Immunol Res. 2019;7(4):644\u201357.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"730_CR42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2567.2001.01220.x","volume":"103","author":"K Rosner","year":"2001","unstructured":"Rosner K, Winter DB, Tarone RE, Skovgaard GL, Bohr VA, Gearhart PJ. Third complementarity-determining region of mutated VH immunoglobulin genes contains shorter V, D, J, P, and N components than non-mutated genes. Immunology. 2001;103(2):179\u201387.","journal-title":"Immunology."},{"key":"730_CR43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3389\/fimmu.2017.00319","volume":"8","author":"LN Adler","year":"2017","unstructured":"Adler LN, Jiang W, Bhamidipati K, Millican M, Macaubas C, Hung SC, et al. The other function: class II-restricted antigen presentation by B cells. Front Immunol. 2017;8:319.","journal-title":"Front Immunol"},{"key":"730_CR44","doi-asserted-by":"crossref","first-page":"8866","DOI":"10.1038\/ncomms9866","volume":"6","author":"S Kasar","year":"2015","unstructured":"Kasar S, Kim J, Improgo R, Tiao G, Polak P, Haradhvala N, et al. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat Commun. 2015;6:8866.","journal-title":"Nat Commun"},{"issue":"1","key":"730_CR45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bjh.15018","volume":"180","author":"P Jain","year":"2018","unstructured":"Jain P, Nogueras Gonzalez GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, et al. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018;180(1):33\u201340.","journal-title":"Br J Haematol"},{"issue":"4","key":"730_CR46","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell. 2017;171(4):934\u201349 e15.","journal-title":"Cell."},{"issue":"6","key":"730_CR47","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.leu.2402528","volume":"16","author":"MJ Dyer","year":"2002","unstructured":"Dyer MJ, Oscier DG. The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia. Leukemia. 2002;16(6):973\u201384.","journal-title":"Leukemia."},{"issue":"1","key":"730_CR48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","volume":"131","author":"ZY Xu-Monette","year":"2018","unstructured":"Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68\u201383.","journal-title":"Blood."},{"issue":"7528","key":"730_CR49","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature."},{"issue":"379","key":"730_CR50","doi-asserted-by":"crossref","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","volume":"9","author":"Whijae Roh","year":"2017","unstructured":"Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9(379).","journal-title":"Science Translational Medicine"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0730-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0730-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0730-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:45:28Z","timestamp":1601055928000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0730-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0730-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"19 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki as part of the International DLBCL Rituximab-CHOP Consortium Program. Data collection protocols were approved as being of minimal to no risk or as exempt by the institutional review board of each participating institution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"B.C. and I.K. are employees of Adaptive Biotechnologies. R.D.B. is a co-founder of ioGenetics LLC. T.S. is a former employee of Adaptive Biotechnologies. K.H.Y. receives research support from Adaptive Biotechnologies, Roche Molecular Diagnostics, Gilead Sciences, Seattle Genetics, Daiichi Sankyo, Incyte Corporation, and HTG Molecular Diagnostics. Other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"272"}}